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Biological markers, i.e., biomarkers, in lung tissue may make it possible to connect cell biological phenomena to the
pathogenetic mechanisms in idiopathic pulmonary fibrosis (IPF). This review focuses on the lung tissue biomarkers,
which have been compared with relevant clinical endpoints or with the most common differential diagnostic lung
diseases. In addition, studies conducted on lung tissue samples and investigated by transcriptomic or proteomic
methodologies have been included. Several studies have observed changes in alveolar epithelium and extracellular
matrix supporting the current hypotheses of the pathogenesis of IPF. In many studies, however, alterations in
inflammatory cells have been revealed, a phenomenon not currently incorporated into pathogenetic theories.
Combining lung tissue material with other non-solid organs with clinically meaningful endpoints may prove to be
the most beneficial approach in the search for non-invasive biomarkers.
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Introduction
Biological markers, which are often referred to as bio-
markers, are commonly defined as objectively measured
and evaluated indicators of physiological or pathological
processes or pharmacological responses to therapeutic
intervention [1], although there are also several other
definitions. During recent years, blood-originated bio-
markers from serum, plasma, or cells have been the
most extensively reviewed with respect to idiopathic pul-
monary fibrosis (IPF) [2,3]. Biomarkers have been postu-
lated to be useful in several ways, e.g., in making a
differential diagnosis between IPF and other interstitial
lung diseases (ILDs), in estimating prognosis and sur-
vival, in revealing the course of disease, and also for
monitoring drug efficacy. In addition, it is possible that
biomarkers could be helpful in distinguishing between
various phenotypes of IPF.* Correspondence: Riitta.Kaarteenaho@oulu.fi
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It has been estimated that about one third of IPF pa-
tients do require a surgical lung biopsy (SLB) in order to
come to an ultimate diagnosis, and thus, it may be feas-
ible to obtain lung tissue samples from a relatively high
proportion of patients [4]. One benefit for lung tissue
biomarkers would be the fact that the tissue obtained is
probably the most appropriate source if one wishes to be
able to link cell biological phenomena to pathogenetic
mechanisms of the disease. Many biomarkers can be
presumably located in several targets. Blood, sputum,
and even broncho-alveolar lavage (BAL) samples can be
collected repeatedly, which is usually not possible for
lung tissue samples taken by surgical operation, because
these procedures always carry a potential risk of serious
complications [4]. The novel less invasive method for
obtaining lung tissue samples by the transbronchial
cryo-biopsy technique is expected to become more com-
mon in clinical practice; this may mean that in the fu-
ture, lung tissue samples could be obtained not only for
diagnostics but also for follow-up [5]. Some blood bio-
markers have been investigated also in BAL and lung tis-
sue, but there are very few reports describing the
simultaneous examination of blood and BAL or lung
tissue samples. The recent study of Seibold et al. com-
bined multiple sources of materials and showed that ae BioMed Central. This is an Open Access article distributed under the terms of
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(MUC5B) was associated with familial interstitial pneu-
monia (IP) and IPF [6].
This review article aims to focus on biomarkers in IPF,
i.e., idiopathic usual interstitial pneumonia (UIP), in lung
tissue concentrating on studies with relevant clinical
endpoints. Studies focusing on IPF and UIP were in-
cluded due to the changes in the classification, which
have taken place during the past decades, although all
UIP cases do not necessarily represent IPF. Publications
comparing IPF with major types of ILDs like nonspecific
interstitial pneumonia (NSIP) and connective tissue
disease-associated ILD (CTD-ILD), which are the most
common differential diagnostic dilemmas, were included.
In addition, studies conducted on lung tissue samples
using modern large-scale transcriptomic and proteomic
technologies were included, although all of those had not
used clinical or radiological endpoints.
Studies on lung tissue samples with clinical endpoints
Studies of fibroblast focus
The specific aggregates of fibroblasts, myofibroblasts,
and extracellular matrix (ECM) proteins in fibrotic lung
are called fibroblast foci (FF), and these structures are
more common in IPF than in other types of lung fibroses.
Several studies have demonstrated that a high amount of
FF in lung tissue correlates with the shortened survival of
IPF patients [7-12], as previously reviewed elsewhere [4].
At present, the number of the FF is the only histological
biomarker that reproducibly correlates with the prognosis
of IPF.
Lung tissue biomarkers with clinical or radiological
endpoints
The majority, 75.8%, of patients with IPF were found
to be positive for protease-activated receptor 2 (PAR-2)
in the study of Park et al. (Table 1). Blood neutrophil
counts were lower, whereas blood lymphocyte counts
and honeycombing scores in chest CT were higher in
PAR-2-positive patients than in the PAR-2-negative pa-
tients. All of the fatal cases belonged to the PAR-2-
positive group, although this difference between groups
did not reach statistical significance [13]. In the study of
Tzouvelikis and co-authors, lung tissue samples of IPF,
cryptogenic organizing pneumonia (COP), and NSIP pa-
tients were analyzed for epidermal growth factor recep-
tor (EGFR). It was observed that the EGFR mRNA levels
negatively correlated with forced vital capacity (FVC)
and diffusion capacity (DLCO) [14].
Todd et al. studied IPF cases using both SLB and sub-
sequent lung transplantation samples from each patient,
which made it possible to compare the histological fea-
tures of the early and late phases of the disease. It was
revealed that numbers of lymphocytes in lung tissueincreased during progression since the amount of lym-
phocytes was higher in the lung explants than in the
SLB samples [15].
IPF cases were investigated for the expression levels of
alpha smooth muscle actin (α-SMA), telomerase, interleu-
kin 4 (IL-4), transforming growth factor-beta (TGF-β),
and beta fibroblast growth factor (β-FGF). It was noted
that the levels of expressions of myofibroblast α-SMA and
IL-4 were negatively associated with patient survival [16].
Calabrese et al. examined explanted lungs of IPF patients,
of which patients with high-grade dysplasia or carcinomas
showed a greater increase in the levels of serpin B3/B4 ex-
pression in metaplastic epithelial cells than the patients
without these diseases. The expression level of serpin B3/
B4 was linearly and positively associated with age. Further-
more, the patients with greater impairments in DLCO dis-
played significantly higher expression of serpin B3/B4 [17].
It was noted that the number of mast cells were in-
creased in IPF, and in addition, a high mast cell number
also associated with a slower rate of decline in FVC in a
study of Cha and co-authors [18]. Nagata and others eval-
uated Krebs von den Lungen-6 antigen (KL-6) and surfac-
tant protein A (SP-A) in idiopathic interstitial pneumonia
(IIP). In patients with IIPs as a whole and also in those
with UIP, the SP-A positive ratio was significantly lower in
those who died from the progression of disease in com-
parison to those patients with another prognosis, i.e.,
stable, improved, and deteriorating but living [19].
Myllärniemi et al. investigated UIP and NSIP cases
for gremlin and bone morphogenetic protein 4 (BMP-4),
revealing that the area of gremlin-positive staining corre-
lated negatively with FVC. The levels of gremlin mRNA
correlated negatively with the specific diffusion capacity
corrected for alveolar volume (DLCO/VA), whereas BMP-
4 mRNA correlated positively with FVC and DLCO [20].
A negative correlation between gremlin mRNA levels and
DLCO/VA was observed when UIP and NSIP patients were
analyzed. In contrast, a positive correlation was observed
between BMP-4 mRNA and FVC as well as between BMP-4
mRNA and DLCO.
Parra et al. revealed that the total density of inflamma-
tory cells was significantly increased in the patients with
NSIP and diffuse alveolar damage (DAD) when compared
to those with UIP. In UIP, forced expiratory volume in 1 s
(FEV1) and survival correlated with the numbers of CD3-
positive T lymphocytes (TL), the numbers of CD68-
positive cells correlated with FEV1, and the amounts of
neutrophil elastase-positive cells correlated with residual
volume and residual volume/total lung capacity (TLC)
and carbon monoxide transfer factor. The most important
predictor of survival in UIP/IPF was CD3-positive TLs
[21]. In another study it was found that in IPF, the num-
bers of CD8-positive TLs inversely correlated with FVC%
predicted, TLC% predicted, DLCO% predicted, and arterial
Table 1 Compilation of studies using lung tissue biomarkers with clinical endpoints
Study Patients/sample type Biomarker/method Clinical endpoint Main results
[13] 33 IPF PAR-2 Honeycombing in chest CT Honeycombing, blood neutrophils, and
lymphocytes increased in PAR-2-positive cases
Inflammatory cells in
blood and BAL
All fatal cases were PAR-2-positive
SLB IHC All-cause mortality
[14] 20 IPF EGFR Lung function EGFR mRNA negatively correlated with FVC
and DLCO





















[18] 29 IPF Chymase Change in FVC over
6-month period
Mast cell number associated slower rate
decline in FVC in IPF
16 HP CAE










[20] 24 UIP Gremlin Lung function Gremlin mRNA correlates negatively with
DLCO/VA and BMP-4 mRNA positively
with FVC and DLCO12 NSIP BMP-4 Differential diagnostics
SLB IHC Gremlin + area in IHC correlated negatively
with FVC
Lung transplant RT-PCR
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Table 1 Compilation of studies using lung tissue biomarkers with clinical endpoints (Continued)
[21] 20 IPF-UIP CD68, anti-elastase,
CD3, CD4, CD8
Lung function FEV1 and survival correlated with CD3+ TLs,
and CD68+ cells correlated with FEV1 in IPF




[22] 12 IPF CD68, anti-elastase,
CD3, CD4, CD8
Lung function CD8+ TLs correlated inversely with FVC%
pred, TLC% pred, DLCO% pred, and PaO2
SLB IHC PaO2
Dyspnea score
[23] IPF 29 LMP-1 Survival LMP-1+ associated with death due to
respiratory failure and use of systemic steroid
SSc-ILD 5 Differential diagnostics
SLB IHC Systemic steroid
treatment
PCR
[24] 28 UIP Tenascin-C Survival High tenascin-C expression correlated with









IPF idiopathic pulmonary fibrosis, SLB surgical lung biopsy, IHC immunohistochemistry, CT computed tomography, PAR-2 protease-activated receptor 2, BAL
broncho-alveolar lavage, HC histochemistry, α-SMA alpha smooth muscle actin, IL-4 interleukin 4, TGF-β transforming growth factor-beta, FGF fibroblast growth
factor, qRT-PCR quantitative reverse transcriptase polymerase chain reaction, DLCO diffusion capacity, HP hypersensitivity pneumonitis, SSc-ILD systemic sclerosis
associated interstitial lung disease, CAE chloroacetate esterase, UIP usual interstitial pneumonia, FVC forced vital capacity, NSIP nonspecific interstitial pneumonia,
COP cryptogenic organizing pneumonia, BOOP bronchiolitis obliterans organizing pneumonia, RB-ILD respiratory bronchiolitis interstitial lung disease, SP-A surfactant
protein A, KL-6 Krebs van den Lungen-6 antigen, BMP-4 bone morphogenic protein 4, AIP acute interstitial pneumonia, DAD diffuse alveolar damage, CD cluster of
differentiation, FEV1 forced expiratory volume in 1 s, PaO2 arterial oxygen tension, LMP-1 latent membrane protein 1, DIP desquamative interstitial pneumonia,
IEM immunoelectron microscopy, EGFR epidermal growth factor receptor, TLC total lung capacity, TL T lymphocytes, AA allergic alveolitis.
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correlations were found between the numbers of
CD8-positive TLs and alveolar-arterial gradient (P(A-a)O2)
as well as the Medical Research Council (MRC) score.
Furthermore, the CD8-positive TLs displayed significant
negative correlations with the FVC% predicted and the
FEV1% predicted [22].
Tsukamoto et al. observed that epithelial cells were
positively stained for Epstein-Barr virus-associated latent
membrane protein 1 (LMP1) in 31% of the patients with
IPF, whereas none of the patients with systemic sclerosis
(SSc)-associated ILD or the controls showed this kind of
positive staining. Death from respiratory failure was sig-
nificantly more common in LMP1-positive patients than
in LMP1-negative patients. The use of systemic steroids
after lung biopsy was more frequent in the LMP-positive
than in the LMP-negative patients [23].
The amount of tenascin-C was analyzed in patients
with UIP and also other types of ILDs [24]. The mean
survival of the patients with UIP with high scores oftenascin-C was significantly shorter than that of patients
with UIP with a lower tenascin-C sum score. Testing of
tenascin-C scores in different locations revealed that an
increased accumulation of tenascin-C underneath meta-
plastic bronchiolar-type epithelium was also associated
with a shorter survival.
Differential diagnostic biomarkers
Cipriani et al. investigated CTD-UIP and IPF to evaluate
the count and area of both FF and lymphocyte aggre-
gates (LAs) (Table 2). They found that FF counts and
areas were lower in patients with CTD-UIP, whereas the
LA counts and areas were greatest in the patients with
CTD-UIP, although the differences did not quite reach
statistical significance. The only marked difference was
observed in NSIP features, which were more prevalent in
CTD-UIP than in idiopathic UIP [25]. NSIP and IPF cases
were evaluated for levels of chemokine receptors CXCR3
and CCR4. It was found that the number of CXCR3-
positive lymphocytes in NSIP patients was significantly
Table 2 Examples of studies focusing on differential diagnostics between IPF and NSIP or CTD-ILD
Study Patients/sample type Biomarker/method Main results
[25] 17 CTD-UIP FF count/area Lower FF counts/areas in CTD-UIP
18 IPF-UIP LA count/area Higher LA counts/areas in RA-ILD
NSIP features Higher prevalence of NSIP in CTD-UIP
SLB
Lung transplant HC
[26] 12 NSIP CXCR3 CXCR3+ lymphocytes higher in NSIP
10 IPF CCR4 CCR4+ lymphocytes higher in IPF
SLB IHC










[29] 26 IPF-UIP MMP-2, MMP-9, TIMP-2 More MMP-9 in IPF
11 NSIP More MMP-2 in NSIP and BOOP
6 BOOP
SLB IHC
CTD connective tissue disease, UIP usual interstitial pneumonia, IPF idiopathic pulmonary fibrosis, ILD interstitial lung disease, RA rheumatoid arthritis, SLB surgical
lung biopsy, FF fibroblast focus, LA lymphocyte aggregates, NSIP nonspecific interstitial pneumonia, HC histochemistry, CXCR and CCR chemokine receptors, IHC
immunohistochemistry, p53 tumor protein p53, Mdm2 mouse double minute 2 homolog, Bax apoptosis regulator Bax, p21 cyclin-dependent kinase inhibitor 1,
TUNEL a method detecting DNA fragmentation resulting from apoptosis, BOOP bronchiolitis obliterans organizing pneumonia, MMP matrix metalloproteinase, TIMP
specific tissue inhibitor of metalloproteinase.
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number of CCR4-positive lymphocytes in NSIP patients
was significantly lower than that in IPF, and thus, the
CXCR3 to CCR4 ratio in the NSIP patients was signifi-
cantly elevated [26].
The levels of epimorphin protein and mRNA expression
in NSIP were significantly higher than those in the pa-
tients with UIP in the study of Terasaki and co-authors
[27]. Nakashima et al. evaluated IPF and NSIP cases for
signaling molecules associated with tumor protein p53-
mediated apoptosis [28]. Western blotting revealed that
the expression of p53, phosphorylated p53, and mouse
double minute 2 homolog (Mdm2) protein was signifi-
cantly higher in IPF and NSIP than in the controls. The
numbers of cells positive for the p53, phosphorylated
p53, Mdm2, and apoptosis regulator Bax proteins as well
as the number of TUNEL-positive cells were higher in
IPF than in NSIP. Suga et al. investigated cases with IPF,
NSIP, and bronchiolitis obliterans organizing pneumonia
(BOOP) for various matrix metalloproteinases (MMP) andthe specific tissue inhibitors of metalloproteinases (TIMP)
[29]. The intense expression of MMP-9 in metaplastic
epithelial cells was a special characteristic of UIP.
Studies focusing on omics techniques
Zuo et al. conducted a microarray analysis of lung speci-
mens from the patients with IPF and CTD-UIP (Table 3).
A marked increase in the expression of genes that en-
code for muscle proteins was observed. The expression
of genes that encode for proteins associated with cell
contraction and actin filament organization was in-
creased as well as that of genes encoding for collagens I,
III and VI, tenascin-C, osteopontin, and fibronectin [30].
Selman et al. investigated lung tissues from the patients
with IPF, hypersensitivity pneumonitis (HP), and NSIP
by microarray [31]. IPF cases were enriched for genes
involved in development, extracellular matrix structure
and turnover, and cellular growth and differentiation.
The levels of several epithelium-related genes were also
upregulated in IPF lungs.
Table 3 Omic studies using lung tissue in IPF research
Study Patients/sample type Method Factors in IPF
[30] 3 IPF-UIP Oligonucleotide microarray Muscle and smooth muscle markers, ECM proteins,
factors associated with ECM formation, cell contraction,
and actin filament organization increased in UIP2 CTD-UIP
3 controls from lung cancer
surgery
5 controls from CLONTECH
SLB
[31] 15 IPF Affymetrix oligonucletide DNA microarray Genes involved in development, epithelium,
ECM structure/turnover, cellular growth, and




[32] 14 IPF Whole human genome oligonucleotide
microarray
Factors involved in ECM turnover, structural
constituents and degradation, and cell adhesion
molecules increased in IIP2 NSIP





[33] 23 IPF (stable) Agilent 4 × 4 whole human genome
microarray
579 genes expressed differently in IPF and
IPF-AEx: heat shock proteins, alpha-defensins,




[34] 6 stable or slowly progressive IPF Serial analysis of gene expression (SAGE) About 100 of transcripts upregulated in progressive IPF
6 progressive IPF
SLB
[35] 119 IPF-UIP Affymetrix Elevated expression of cilium genes associated
with microscopic honeycombing, MUC5B, and MMP-7
50 controls Microarray
Lung tissue samplesa RT-PCR
[36] 14 IPF Proteome analysis: two-dimensional
gel electrophoresis and MALDI-TOF-MS
51 upregulated and 38 downregulated proteins in IPF
10 controls (donors)
Lung transplant IHC
[37] IPF 14 2-dimensional DIGE technique and
MALDI-TOF-MS
Stress-induced genes upregulated in IPF and fNSIP
fNSIP 8
Controls 10 (organ donors)
Lung transplant
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Table 3 Omic studies using lung tissue in IPF research (Continued)
[40] 94 IPF Agilent gene expression microarray 2,130 DMRs of which 738 associated with changes
in gene expression
67 controls CHARM array
Lung tissue samplesa
UIP usual interstitial pneumonia, IPF idiopathic pulmonary fibrosis, CTD connective tissue disease, ECM extracellular matrix, HP hypersensitivity pneumonitis, NSIP
nonspecific interstitial pneumonia, IIP idiopathic interstitial pneumonia, SLB surgical lung biopsy, AEx acute exacerbation of IPF, CCNA2 cyclin A2, MUC5B mucin-5
subtype B, MMP matrix metalloproteinase, fNSIP fibrotic nonspecific interstitial pneumonia, DMR differentially methylated regions, IHC immunohistochemistry,
RT-PCR reverse transcriptase polymerase chain reaction.
aLung tissue specimens (type not specified) obtained from the Lung Tissue Research Consortium.
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with sporadic pulmonary fibrosis and patients with
familial pulmonary fibrosis. The genes involved in ECM
turnover, ECM structural constituents, proteins involved
in ECM degradation, and cell adhesion molecules were
increased. Most of the genes that were differentially
expressed in the familial IIP belonged to the same functional
categories as those that distinguished IIP from control
samples, but they were over- or under-expressed to a greater
extent in familial IIP than in all cases of IIP [32].
Konishi et al. evaluated lungs from the patients with
stable IPF and patients with acute exacerbation of IPF
(IPF-AEx) by microarrays. When compared with control
samples, the global gene expression patterns of IPF-AEx
were almost identical to those of stable IPF. In the direct
comparison of IPF-AEx and stable IPF, the differentially
expressed genes included those related to stress re-
sponses such as heat shock proteins and α-defensins as
well as mitosis-related genes including histones and
cyclin-A2 protein (CCNA2) [33]. The study of Boon and
co-authors compared stable or slowly progressing IPF
patients with those suffering from progressive IPF. It
was found that about a 100 of transcripts were upregu-
lated in the progressive group [34].
Yang et al. conducted a microarray analysis of 119 IPF
cases and 50 controls. There was elevated expression
of the cilium genes associated with microscopic honey-
combing as well as higher expression of MUC5B and
MMP-7. Two novel subtypes of IPF/UIP could be de-
fined by the expression of cilium-associated genes [35].
Patients with high cilium gene expression demonstrated
more microscopic honeycombing, but not FF, and dis-
played elevated tissue expression of MUC5B and MMP7.
A proteome analysis of explanted lungs from IPF pa-
tients identified that many proteins upregulated in the
IPF fell into the related categories of unfolded protein
response (UPR), endoplasmic reticulum (ER) stress, pro-
teasome, degradation, and general cell stress response
[36]. Subsequently, the same researchers evaluated IPF
and fibrotic NSIP patients with proteomics and noted
that the majority of the proteins which were upregulated
in IPF and NSIP fell into the related categories such as
chaperone/protein folding, protein processing, energy
generation/glycolysis, and antioxidant function [37].Patel et al. studied IPF patients with pulmonary hyper-
tension (PH-IPF) and IPF patients without PH (NPH-
IPF). The comparison of PH-IPF arteriole with NPH-IPF
arteriole results achieved no separation between the two
groups. When gene expression of the combined IPF
samples was compared to the controls, a total of 255
genes were differentially expressed in IPF arterioles [38].
In a gene expression microarray study of DePianto et al.,
microscopic pathological heterogeneity in IPF lung tissue
corresponded to patterns related to bronchiolization and
lymphoid aggregates [39]. Recently, researchers were able
to identify 2,130 differentially methylated regions in IPF, of
which 738 were associated with significant changes in
gene expression [40].Discussion
The current guidelines recommend that in the diagnostics
of IPF, high resolution computed tomography (HRCT)
has to be classified into three categories, i.e., 1) UIP, 2)
probable UIP, or 3) not UIP [41]. If other diseases mani-
fested as UIP are excluded, and if typical UIP is revealed
in HRCT, then the diagnosis of IPF can be established on
the basis of clinical and radiological investigations. When
HRCT is categorized as possible UIP or not UIP, an exam-
ination of surgical lung biopsy is needed in order to make
a reliable diagnosis, which is a multidisciplinary process
and needs to be based on inputs from clinicians, radiolo-
gists, and pathologists [41].
The recent workshop on IPF emphasized three research
foci, i.e., 1) alveolar injury, 2) cellular origins of myofibro-
blasts, and 3) role of stem/progenitor cells [42]. The
present hypothesis of the pathogenesis of IPF indicates
that injured and hyperplastic alveolar epithelia containing
dysfunctional type II alveolar epithelial cells (AECII) are
able to release factors causing proliferation of fibroblasts
and myofibroblasts and deposition of ECM [43]. The
pathogenesis of IPF resembles that of abnormal wound
healing, a process involving many cell biological mecha-
nisms including TGF-β and cellular stress [44]. The origin
of the myofibroblasts in IPF is not yet totally clear,
although several sources have been presented, e.g., that
myofibroblasts arise from resident tissue fibroblast and
bone marrow-derived cells, by epithelial mesenchymal
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cytes, or from fibrocytes [43].
The levels of SP-A in alveolar epithelium have been
shown to be lower in UIP patients dying from progres-
sive disease in comparison with the patients with a
stable disease, a finding which may reflect dysfunction of
AECII [19]. The theory of epithelial damage has received
further support from a study that used proteomics to
reveal that many of the upregulated proteins in IPF
belonged to the related categories of UPR and ER stress
[36]. The finding in proteomics was also confirmed by
immunohistochemistry highlighting that UPR markers
were encountered in AECII cells in IPF but not in
control cells [36]. The discoveries at the protein level
are supported by a transcriptomic investigation, which
showed that several epithelium-related genes were up-
regulated in IPF lungs [31]. A recent study has observed
that the levels of cilium genes and MUC5B were in-
creased in IPF and that cilium genes associated with
microscopic honeycombing showing that not only alveo-
lar but also bronchiolar epithelial alteration may have a
role in the pathogenesis of IPF [35].
TGF-β-induced enhancement of ECM plays a funda-
mental role in the pathogenetic theories of IPF. Grem-
lin, an antagonist of BMP, which is a member of the
TGF-β superfamily, has been shown to associate with
lung function parameters in IPF [20]. High expressions
of tenascin-C, an ECM protein, have been displayed to
correlate with the shortened survival of the patients
[24]. Surprisingly, few other immunohistochemical stud-
ies have been published on ECM alteration compared
with clinical endpoints, whereas several studies have
confirmed by transcriptomics that gene expression of
various ECM proteins including collagens, tenascin,
osteopontin, fibronectin, and genes involved in ECM
regulation is upregulated in IPF [30-32]. The amount of
α-SMA, which is a marker of myofibroblast, has been
shown to associate negatively with patient survival in an
immunohistochemical study [16], and an increased ex-
pression of the genes that code the factors associating
with a myofibroblast has been presented by microarray
studies [30,31]. Moreover, the high number of FF in
lung tissue, in which myofibroblasts and ECM proteins
are localized, has been shown to correlate with the
shortened survival of the patients with IPF [4].
Many immunohistochemical studies have detected
changes in the numbers of inflammatory cells in lung
tissue of IPF, a finding which is not markedly supported
by the current hypotheses. A recent study revealed that
the amount of inflammatory cells did not decrease dur-
ing the progression of the IPF as previously assumed by
many [15]. Moreover, the number of mast cell has been
shown to correlate with the progression of the disease
[18], CD3-positive lymphocytes to correlate with FEV1and survival [21], and CD68-positive T lymphocytes with
lung function changes [22]. Furthermore, histological
heterogeneity in IPF lung tissue corresponded to gene
expression pattern related to lymphoid aggregates [39].
During the past decade, the research on IPF has fo-
cused on blood biomarkers, which is understandable
since blood biomarkers can be easily obtained and ana-
lyzed, also repeatedly. At present, the most widely stud-
ied blood-derived biomarkers have been KL-6 and SP-A
and -D [3]. As outlined in a recent review, a molecular
biomarker in IPF should be quick, non-invasive, inex-
pensive, easy to repeat, and ideally blood or urine based
[45]. Some blood biomarkers have been investigated also
in BAL and lung tissue, but so far, there is a paucity of
publications that have used simultaneously blood and
BAL or lung tissue samples. It could be hypothesized,
however, that the most reliable blood-derived biomarker
could be found based on lung tissue analyses with the
knowledge of cell-specific localization and with an estab-
lished association with the course and the phenotype of
the disease. In addition to the routine clinical follow-up
investigations, it would be important to incorporate
standardized staging and predictor models, such as GAP
(gender, age, physiology) index, in any comparisons in-
volving lung tissue biomarkers [46].
Conclusions
Studying lung tissue in IPF is not an easy task when the
missing key cell type or event in the pathogenesis of IPF
causes discrepant analysis protocols in histological stud-
ies. Can we afford to ignore lung tissue samples when
the pathogenesis of the disease and characterization of
the phenotypes still leave so many unanswered ques-
tions? In addition to supplementing lung tissue material
with other non-solid organs like blood, urine, and BAL,
also the combination of multiple methods like omics, im-
munohistochemistry, protein assays, and mRNA quantifi-
cation together with clinically meaningful endpoints may
well prove to be the most beneficial approach with which
to discover relevant non-invasive biomarkers. This kind of
approach would hopefully make such progress so that
within 10–15 years, rapid and reliable blood-based bio-
markers will have become available not only for research
purposes, but they will have become routine procedures
also in clinical practice.
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arterial gradient; PAR-2: Protease-activated receptor 2; PaO2: Arterial oxygen
tension; PH-IPF: Idiopathic pulmonary hypertension patients with pulmonary
hypertension; p21: Cyclin-dependent kinase inhibitor 1; p53: Tumor protein
p53; RT-PCR: Reverse transcriptase polymerase chain reaction;
qRT-PCR: Quantitative reverse transcriptase polymerase chain reaction;
α-SMA: Alpha smooth muscle actin; SLB: Surgical lung biopsy; SP-A: Surfactant
protein A; SP-D: Surfactant protein D; SSc-ILD: Systemic sclerosis associated
interstitial lung disease; TGF-β: Transforming growth factor-beta; TIMP: Specific
tissue inhibitor of metalloproteinase; TLC: Total lung capacity; TL: T lymphocytes;
TUNEL: A method detecting DNA fragmentation resulting from apoptosis;
UIP: Usual interstitial pneumonia; UPR: Unfolded protein response.
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